Revolutionizing Diabetes Care: Insights on Glargine U300 Insulin
Dr. Sudhir Tripathi highlights the key attributes of Glargine 300 for glycaemic control, focusing on its efficacy and safety. This drug is highly effective, crucial for patients needing good glycaemic control. It has demonstrated a reduction in the risk of hypoglycaemia during the first two weeks of treatment compared to I-Deg, showcasing its safety profile.
Flexibility is another significant advantage; the drug can be administered up to three hours before or after the scheduled time, accommodating patients with varying schedules, including international travel. It also reduces glycaemic variability and significantly improves Time in Range (TIR) in type 1 diabetes patients compared to other basal insulins.
Moreover, Gla-300 can be used in pregnancy if clinically indicated, making it a versatile option.
The morning friends, I am Dr. Sudhir Tripathi and the chairperson in health department of independence and technology at the Sargangaram hospital in New Delhi. The most important factor regarding this drug is the fact that it is a efficacious drug and it is important that it is used in patients who need good glycemic control. Apart from its efficacy, the most second most important factor is the safety of the drug and during this first two weeks of treatment with this drug, when it was compared with I-Day, it was found that it caused a reduction in the risk of hypoglycemia. So therefore this efficacy and safety, there are two most important factors which one thinks about when one is using a drug. Apart from these two factors, the most important other factor is the flexibility of the drug. We have seen that this drug can be used about three hours either before or after the scheduled time of its use in a particular patient. That means a patient can have a lot of flexibility when using the drug, particularly when one is in dialing in international travel, when one can use a drug either three hours or three hours after the scheduled time of the drug. The other important factor when using his drug is the glycemic variability. Recently I have shown that glycemic variability is a very important factor when one treats a patient with type 1 diabetes. So you have this patient who can be given the Gladins 300 and Gladins 300 reduces the glycemic variability and the time in range is increased significantly when compared with the other basal insulin. The next factor which one would transfer is the use during pregnancy. We have seen that during pregnancy in diabetes or in gestational diabetes, the use of basal insulin is very important in controlling the pre-prandial blood sugar levels. And apart from the previously used insulin, the currently used insulin in the second generation basal insulin including the Gladins 300 can be used anytime during gestational diabetes if it is indicated, safe and effective. The other most important factor is the cost of the drug. We have seen that Gladins 300 is about 35% cheaper than the other second generation insulin that is available at ID. Thank you for the day.
Dr. Suddhi Tripathi highlights the key attributes of a new drug for glycemic control, focusing on its efficacy and safety. This drug is highly effective, crucial for patients needing good glycemic control. It has demonstrated a reduction in the risk of hypoglycemia during the first two weeks of treatment compared to I-Day, showcasing its safety profile.
Flexibility is another significant advantage; the drug can be administered up to three hours before or after the scheduled time, accommodating patients with varying schedules, including international travel. It also reduces glycemic variability and significantly improves Time in Range (TIR) in type 1 diabetes patients compared to other basal insulins.
Moreover, this drug is safe and effective for use during pregnancy, including in cases of gestational diabetes, making it a versatile option. Additionally, it is 35% cheaper than other second-generation insulins, making it a cost-effective choice for managing diabetes.
00:00:13 to 00:00:42
Rosenstock J, et al. Diabetes Care 2018;41:2147-54
00:00:44 to 00:01:57
1. Gla-300 Prescribing information. Dated: Sept 2022,Source CCDS Version 5 dated 10th Sept 2020 2. Lucidi P. et.al. Diabetes Care.2021;44(1):125-132.
3. Battelino T, et al. Diabetes Ther 2020;11(4):1017-1027;
4. Battelino T, et al. Diabetes Ther 2020;11(7):1907-1908;
5. Battelino, et al. Oral presentation at ATTD Congress 2022, April 29).
00:01:56 to 00:02:08
Ref: For Gla-300: MRP of 4.5ml cartridge as on Dec 2023 = Rs 1400; For IDEG-100; MRP of 3 ml cartridge as on Dec 2023 = Rs 1440
